Skip to main content
Figure 7 | BMC Pharmacology

Figure 7

From: Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist

Figure 7

Effect of CE-178253 on FI (7A) and BW (7B) in chow-fed rats. FI and BW were measured in chow-fed rats, treated after once daily administration of veh. (0.5% MC) or CE-178253 at either 3 mg/kg or 10 mg/kg p.o. Initial and final body weights of veh-treated rats were 435 ± 11 g and 451 ± 12 g (n = 8), respectively. Initial and final body weights of 3 mg/kg CE-178253-treated rats were 436 ± 9 g and 427 ± 9 g, respectively. Initial and final body weights of 10 mg/kg CE-178253-treated rats were 435 ± 11 g and 430 ± 10 g, respectively. FI data shown are the total amount of food consumed expressed in grams for each day of treatment. The mean ± SEM (n = 6-8/group) is shown. * = p < 0.05 vs. veh.

Back to article page

BMC Pharmacology

ISSN: 1471-2210